Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment

Core Viewpoint - Halberd Corporation has acquired NeuroSense AI Corp., which offers a revolutionary AI platform for behavioral analysis aimed at transforming research and clinical assessment for traumatic brain injury (TBI) and other medical applications [2][3][4]. Company Overview - Halberd Corporation (OTC: HALB) is a technology holding company focused on developing innovative healthcare solutions, including AI-powered platforms and diagnostic technologies [16]. - NeuroSense AI Corp. is an 89%-owned subsidiary of Halberd, specializing in behavioral intelligence through advanced AI and multi-modal sensor technology [13][14]. Technology and Innovation - The NeuroSense AI platform integrates three behavioral data streams: vocal patterns, movement dynamics, and social interactions, utilizing Claude AI technology for advanced analysis [3][5]. - This multi-modal approach generates comprehensive behavioral fingerprints, allowing for unprecedented accuracy in tracking recovery trajectories and assessing treatment efficacy [6]. - The platform is designed to be scalable, supporting studies from individual labs to large multi-site clinical trials, with future applications extending to human clinical assessments [14][11]. Market Potential - The global behavioral health market is projected to reach $240 billion by 2030, with AI-driven diagnostic tools expected to be the fastest-growing segment [7]. - Halberd Corporation positions itself as a first mover in commercializing Claude AI-powered behavioral analysis, providing a competitive edge in both research and clinical markets [7][8]. Applications - NeuroSense AI has immediate applications across various sectors: - Research Institutions: Enhancing TBI studies and data quality [9]. - Clinical Applications: Offering objective tools for tracking patient progress and optimizing treatment protocols [9]. - Pharmaceutical Development: Supporting clinical trials and regulatory submissions with robust behavioral endpoint data [9]. - Government and Military: Applications include personnel assessment and long-term health monitoring for service members [10]. Regulatory Readiness - The NeuroSense AI platform is being developed with FDA regulatory pathways in mind, featuring comprehensive documentation and clinical-grade accuracy standards [11].